Regenxbio (RGNX) Stock Price, Quote, News & History | Benzinga

SPY761.10−1.39%QQQ707.87−2.77%BTC/USD81,311.13−0.23%DIA518.00−0.59%GLD381.40−0.34%TLT80.06+0.11%

Regenxbio Inc (RGNX) Stock Price, Quote, News & History

RGNXNASDAQ

Trade with Public

Trade with Public

$6.92

-0.24-3.28%

Last update: Oct 16, 3:59 PM

$7.15

-0.01-0.14%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$7.14

Close

$6.93

Volume / Avg.

984.69K / 1.49M

Day Range

$6.92 - $6.97

52 Wk Range

5.46 - 16.19

Market Cap

$454.17M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

33

Short Interest

15.41%

Days to Cover

5.99

Recent REGENXBIO Inc. News

Crude Oil Down 3%; XPeng Shares Fall After Q2 Results

US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected loss and lower revenue outlook.

Avi Kapoor

Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold

Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.

Vandana Singh

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.

Avi Kapoor

This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

Wall Street analysts changed outlook on top names. For rating changes, check our analyst ratings page. See analysts' views on ADIG, TSEM and more

Avi Kapoor

This HubSpot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top Wall Street analysts changed outlook on top names. For all changes & stock ratings, see analyst ratings page. Some stocks downgraded & price targets lowered.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-246.67M

Investing Cash Flow (TTM)

216.34M

Financing Cash Flow (TTM)

-12.74M

Free Cash Flow (TTM)

-249.67M

Capital Expenditure (TTM)

-2.99M

Net Change in Cash (TTM)

-43.07M

Analyst Trends and Forecast

2

May

4

Jun

3

1

Aug

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$436.09M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.14

PB Ratio (TTM)

6.59

Earnings Yield % (TTM)

-52.79%

Earnings Yield % (FWD)

-39.32%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.09

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-$33.00K

LT Debt Repayment (TTM)

-

Total Cash

$36.49M

Debt to Equity

0.96

Issuance of Debt (TTM)

-$33.00K

Repayment of Debt (TTM)

-